GFRAL
GFRAL (GDNF family receptor alpha like, also known as GRAL, UNQ9356, bA360D14.1 and C6orf144) is a cell-membrane receptor for the hormone GDF15. It is restricted to the brainstem and mediates an aversive response to stress that includes nausea, vomiting and loss of appetite. Browse Assay Genie's current range of GFRAL research reagents below, or read on for the biology behind the target.
GFRAL is a brainstem-restricted receptor for GDF15. When GDF15 binds, GFRAL triggers an aversive response, characterised by nausea, vomiting and/or loss of appetite, in reaction to various stresses. This response is described as both reducing continuing exposure to a stress at the time it occurs and promoting avoidance behaviour in future. Stresses that engage the GDF15-GFRAL axis include anticancer drugs such as camptothecin and cisplatin, cancers, and drugs such as metformin.
Upon interaction with its ligand, GFRAL mediates GDF15-induced autophosphorylation and activation of the RET tyrosine kinase receptor, which leads to activation of MAPK and AKT signalling pathways. Ligand binding activates GFRAL-expressing neurons in the area postrema and nucleus tractus solitarius of the brainstem. The GDF15-GFRAL signal also induces expression of genes involved in metabolism, such as lipid metabolism in adipose tissues. Gene annotation describes GFRAL as having glial cell-derived neurotrophic factor receptor activity and receptor tyrosine kinase binding activity, and as acting in positive regulation of the MAPK cascade and of phosphatidylinositol 3-kinase/protein kinase B signal transduction.
The human GFRAL gene encodes a plasma membrane protein that belongs to the GDNFR family. It was previously designated chromosome 6 open reading frame 144 (C6orf144), and has the further aliases GRAL, UNQ9356 and bA360D14.1. Mouse and rat orthologs are both named Gfral, so the receptor can be studied in common rodent models of stress-induced appetite loss and metabolism.
GFRAL mediates the GDF15-driven aversive response of nausea, vomiting and loss of appetite, making it central to studies of stress-induced anorexia.
The GDF15-GFRAL response is triggered by cancers and by anticancer drugs such as camptothecin and cisplatin, linking the receptor to treatment-related side effects.
GFRAL mediates GDF15-induced autophosphorylation of RET, leading to MAPK and AKT activation, so it is a model for co-receptor signalling.
GFRAL-expressing neurons in the area postrema and nucleus tractus solitarius respond to GDF15, and the signal induces lipid metabolism genes in adipose tissue.
GFRAL is the brainstem receptor for GDF15. Ligand binding activates GFRAL-expressing neurons in the area postrema and nucleus tractus solitarius, and triggers an aversive response with nausea, vomiting or loss of appetite. It also mediates GDF15-induced activation of RET, leading to MAPK and AKT signalling.
GFRAL stands for GDNF family receptor alpha like. Aliases include GRAL, UNQ9356 and bA360D14.1, and the previous symbol C6orf144 comes from the earlier name chromosome 6 open reading frame 144. UniProt lists the protein name as GDNF family receptor alpha-like.
Yes. Mouse and rat both have a Gfral ortholog, and the protein belongs to the GDNFR family. Researchers can therefore examine GDF15-GFRAL biology in rodent models; check the datasheet of any product for its validated reactivity.
Ligand, co-receptor and downstream signalling targets connected to the GDF15-GFRAL pathway.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q6UXV0; product specifications from Assay Genie datasheets.